Acadia Pharmaceuticals Inc ACAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Trading Information
- Previous Close Price
- $18.14
- Day Range
- $18.00–18.76
- 52-Week Range
- $15.86–30.96
- Bid/Ask
- $18.55 / $18.80
- Shares Outstanding
- 172.83M
- Market Cap
- $3.24B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 30.35
- Price/Sales
- 2.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 798
- Website
- https://www.acadia.com
Valuation
Metric | ACAD |
|---|---|
Price/Earnings (Normalized) | 30.35 |
Price/Book Value | 2.34 |
Price/Sales | 2.70 |
Price/Cash Flow | 15.46 |
Price/Earnings
ACAD
Financial Strength
Metric | ACAD |
|---|---|
Quick Ratio | 3.48 |
Current Ratio | 3.82 |
Interest Coverage | — |
Quick Ratio
ACAD
Profitability
Metric | ACAD |
|---|---|
Return on Assets (Normalized) | 25.43% |
Return on Equity (Normalized) | 33.58% |
Return on Invested Capital (Normalized) | 30.07% |
Return on Assets
ACAD
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|!fCG#f | LOCK|N?mH | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<KM>#^x | LOCK|s&mN | $99B | |||
| Moderna Inc MRNA | LOCK|s%!hXXc | LOCK|nb | $90B | |||
| argenx SE ADR ARGX | LOCK|W<wlwmT | LOCK|zGz | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?<M^!c | LOCK|rD | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|V@mzQBTm | LOCK|!Hgg | $31B | |||
| Incyte Corp INCY | LOCK|bjknk$c | LOCK|K^ | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^l!yrMg | LOCK|Q>vyp | $22B | |||
| BioNTech SE ADR BNTX | LOCK|&@%F@@P | LOCK|Prn | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|p#lT&% | LOCK|>X | $16B |
United States